Literature DB >> 31964746

Antibiotic Degradation by Commensal Microbes Shields Pathogens.

Mergim Gjonbalaj1, James W Keith1,2, Mytrang H Do1,3, Tobias M Hohl1,4, Eric G Pamer1, Simone Becattini5.   

Abstract

The complex bacterial populations that constitute the gut microbiota can harbor antibiotic resistance genes (ARGs), including those encoding β-lactamase enzymes (BLA), which degrade commonly prescribed antibiotics such as ampicillin. The prevalence of such genes in commensal bacteria has been increased in recent years by the wide use of antibiotics in human populations and in livestock. While transfer of ARGs between bacterial species has well-established dramatic public health implications, these genes can also function in trans within bacterial consortia, where antibiotic-resistant bacteria can provide antibiotic-sensitive neighbors with leaky protection from drugs, as shown both in vitro and in vivo, in models of lung and subcutaneous coinfection. However, whether the expression of ARGs by harmless commensal bacterial species can destroy antibiotics in the intestinal lumen and shield antibiotic-sensitive pathogens is unknown. To address this question, we colonized germfree or wild-type mice with a model intestinal commensal strain of Escherichia coli that produces either functional or defective BLA. Mice were subsequently infected with Listeria monocytogenes or Clostridioides difficile, followed by treatment with oral ampicillin. The production of functional BLA by commensal E. coli markedly reduced clearance of these pathogens and enhanced systemic dissemination during ampicillin treatment. Pathogen resistance was independent of ARG acquisition via horizontal gene transfer but instead relied on antibiotic degradation in the intestinal lumen by BLA. We conclude that commensal bacteria that have acquired ARGs can mediate shielding of pathogens from the bactericidal effects of antibiotics.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antibiotic resistance; gut microbiota; infection

Year:  2020        PMID: 31964746      PMCID: PMC7093146          DOI: 10.1128/IAI.00012-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice.

Authors:  Usha Stiefel; Nicole J Pultz; Jaana Harmoinen; Pertti Koski; Kai Lindevall; Marion S Helfand; Curtis J Donskey
Journal:  J Infect Dis       Date:  2003-10-23       Impact factor: 5.226

Review 2.  Beta-lactamase-producing bacteria in mixed infections.

Authors:  I Brook
Journal:  Clin Microbiol Infect       Date:  2004-09       Impact factor: 8.067

3.  Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.

Authors:  Usha Stiefel; Jaana Harmoinen; Pertti Koski; Susanna Kääriäinen; Nina Wickstrand; Kai Lindevall; Nicole J Pultz; Robert A Bonomo; Marion S Helfand; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Long-term ecological impacts of antibiotic administration on the human intestinal microbiota.

Authors:  Cecilia Jernberg; Sonja Löfmark; Charlotta Edlund; Janet K Jansson
Journal:  ISME J       Date:  2007-05       Impact factor: 10.302

5.  Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization.

Authors:  F Léonard; A Andremont; B Leclerq; R Labia; C Tancrède
Journal:  J Infect Dis       Date:  1989-08       Impact factor: 5.226

6.  The shared antibiotic resistome of soil bacteria and human pathogens.

Authors:  Kevin J Forsberg; Alejandro Reyes; Bin Wang; Elizabeth M Selleck; Morten O A Sommer; Gautam Dantas
Journal:  Science       Date:  2012-08-31       Impact factor: 47.728

7.  In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis.

Authors:  A S Hackman; T D Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

8.  A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.

Authors:  Dana Gebhart; Stephen Lok; Simon Clare; Myreen Tomas; Mark Stares; Dean Scholl; Curtis J Donskey; Trevor D Lawley; Gregory R Govoni
Journal:  mBio       Date:  2015-03-24       Impact factor: 7.867

Review 9.  The role of beta-lactamase-producing-bacteria in mixed infections.

Authors:  Itzhak Brook
Journal:  BMC Infect Dis       Date:  2009-12-14       Impact factor: 3.090

10.  Live to cheat another day: bacterial dormancy facilitates the social exploitation of β-lactamases.

Authors:  Frances Medaney; Tatiana Dimitriu; Richard J Ellis; Ben Raymond
Journal:  ISME J       Date:  2015-10-27       Impact factor: 10.302

View more
  2 in total

Review 1.  Antibiotic Treatment, Mechanisms for Failure, and Adjunctive Therapies for Infections by Group A Streptococcus.

Authors:  Anders F Johnson; Christopher N LaRock
Journal:  Front Microbiol       Date:  2021-11-04       Impact factor: 5.640

2.  Antimicrobial Stewardship Program: Reducing Antibiotic's Spectrum of Activity Is not the Solution to Limit the Emergence of Multidrug-Resistant Bacteria.

Authors:  Rindala Saliba; Assaf Mizrahi; Péan de Ponfilly Gauthier; Le Monnier Alban; Jean-Ralph Zahar; Benoît Pilmis
Journal:  Antibiotics (Basel)       Date:  2022-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.